World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 89 12450 11712 6376 5896 381 42892

Steven Coutre publications per year

The chart shows the history of publications by Steven Coutre between 1981 and 2024, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Steven Coutre published across 44 years, from 1981 to 2024, averaging 9.2 papers a year. Output peaked at 33 publications in 2015. 25 of the 405 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1981 to 2024. Vertical axis: number of publications, 0 to 33. Peak 33 publications in 2015. 1981: 1 publication 1982: 0 publications 1983: 0 publications 1984: 0 publications 1985: 1 publication 1986: 1 publication 1987: 0 publications 1988: 0 publications 1989: 1 publication 1990: 0 publications 1991: 0 publications 1992: 1 publication 1993: 0 publications 1994: 2 publications 1995: 1 publication 1996: 1 publication 1997: 0 publications 1998: 2 publications 1999: 0 publications 2000: 1 publication 2001: 2 publications 2002: 3 publications 2003: 5 publications 2004: 7 publications 2005: 8 publications 2006: 7 publications 2007: 13 publications 2008: 6 publications 2009: 14 publications 2010: 21 publications 2011: 17 publications 2012: 26 publications 2013: 32 publications 2014: 30 publications 2015: 33 publications 2016: 32 publications 2017: 27 publications 2018: 27 publications 2019: 24 publications 2020: 10 publications 2021: 17 publications 2022: 7 publications 2023: 24 publications 2024: 1 publication
1981 2024

405 publications in total across all disciplines

View publications per year as a table
Steven Coutre: publications per year, 1981 to 2024
Year Publications
1981 1
1982 0
1983 0
1984 0
1985 1
1986 1
1987 0
1988 0
1989 1
1990 0
1991 0
1992 1
1993 0
1994 2
1995 1
1996 1
1997 0
1998 2
1999 0
2000 1
2001 2
2002 3
2003 5
2004 7
2005 8
2006 7
2007 13
2008 6
2009 14
2010 21
2011 17
2012 26
2013 32
2014 30
2015 33
2016 32
2017 27
2018 27
2019 24
2020 10
2021 17
2022 7
2023 24
2024 1
Total 405
Download as CSV

Steven Coutre publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Steven Coutre sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 381–400 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 381 publications — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861 381
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Steven Coutre D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Steven Coutre sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 88–89 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970 89
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Steven Coutre is a researcher affiliated with Stanford University in the United States. Their scholarly work primarily falls within the field of Medicine, with a strong focus on Genetics, Pathology and Forensic Medicine, Hematology, Immunology, and Oncology as subfields of study.

Coutre's research outputs emphasize several main topics:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Chronic Myeloid Leukemia Treatments
  • Advanced Breast Cancer Therapies
  • Acute Lymphoblastic Leukemia research
  • Gastrointestinal Tumor Research and Treatment

Among their recent publications are the following:

  • "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial" (2020, The Lancet)
  • "Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia" (2022, Blood Advances)
  • "Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial" (2022, Blood)
  • "Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia" (2022, Leukemia)
  • "Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study" (2020, Clinical Cancer Research)

Frequently collaborating co-authors include:

  • Paolo Ghia
  • John C. Byrd
  • Jennifer A. Woyach
  • Paul M. Barr
  • Harry P. Erba

Steven Coutre has contributed regularly to several publication venues. Notably, their work appears most often in:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Leukemia

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

    Steven L. Soignet;Stanley R. Frankel;Dan Douer;Martin S. Tallman

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

    Jorge E Cortes;Philippe Rousselot;Dong Wook Kim;Ellen Ritchie

  • Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

    Margaret R. O'Donnell;Martin S. Tallman;Camille N. Abboud;Jessica K. Altman

  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

    Jeff P Sharman;Miklos Egyed;Wojciech Jurczak;Alan Skarbnik;Alan Skarbnik

  • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

    Bayard L. Powell;Barry Moser;Wendy Stock;Robert E. Gallagher

  • International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

    A C Rawstron;N Villamor;M Ritgen;S Böttcher

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation : the SPRINT trial

    Jeffrey McCullough;David H. Vesole;Richard J. Benjamin;Sherrill J. Slichter

Frequent Co-Authors

Susan O'Brien
Susan O'Brien University of California, Irvine
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Peter Hillmen
Peter Hillmen St James's University Hospital
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Jennifer R. Brown
Jennifer R. Brown Harvard University
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean committing to medical school. There are many medical billing and coding online schools that offer flexible programs, letting students quickly enter the healthcare field and work behind the scenes. For those interested in direct patient care, bridge programs like lpn to rn programs without teas test requirements can make advancing in nursing more accessible than ever.

If you’re considering a leadership path, pursuing an online healthcare management degree can be a smart move. These programs teach crucial skills in management and policy, opening doors to administrative roles in hospitals or clinics. Nurses wanting to level up can look into asn to np programs, which provide a faster route to becoming a nurse practitioner.

These online degree pathways offer flexibility, financial aid, and quicker career advancement—ideal for those passionate about healthcare but seeking alternatives to traditional medical degrees.

Best Scientists Citing Steven Coutre

Trending Scientists

Recently Published Articles